Published in J Mol Diagn on November 30, 2011
MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One (2013) 1.71
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J Clin Med (2015) 1.48
MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res (2012) 1.43
Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid. Front Genet (2013) 1.23
MicroRNA detection in plasma samples: how to treat heparinized plasma. J Mol Diagn (2013) 1.12
Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int (2015) 1.08
Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One (2013) 1.08
Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer. Dis Markers (2015) 1.01
Data Normalization Strategies for MicroRNA Quantification. Clin Chem (2015) 1.00
Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform (2015) 0.98
Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods (2012) 0.98
MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives. Genes Dis (2014) 0.94
Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cell Biochem (2014) 0.92
Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front Physiol (2012) 0.90
Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. Drug Metab Dispos (2013) 0.88
Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. Neurotherapeutics (2013) 0.85
Circulating microRNA Profile throughout the menstrual cycle. PLoS One (2013) 0.84
Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients. Mol Diagn Ther (2014) 0.81
Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci (2014) 0.80
Identification of extracellular miRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple methods. Mol Biol Rep (2016) 0.79
Optimized microRNA purification from TRIzol-treated plasma. BMC Genomics (2015) 0.79
Expression profiling analysis of the microRNA response of Cynoglossus semilaevis to Vibrio anguillarum and other stimuli. Mar Biotechnol (NY) (2015) 0.78
Contact Transfer Printing of Side Edge Prefunctionalized Nanoplasmonic Arrays for Flexible microRNA Biosensor. Adv Sci (Weinh) (2015) 0.78
Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease. Biomed Res Int (2016) 0.77
Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms. Dis Markers (2015) 0.76
Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One (2014) 0.76
Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. BMC Bioinformatics (2015) 0.76
B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2017) 0.75
Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs. Biomol Detect Quantif (2016) 0.75
Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies. World J Surg Oncol (2014) 0.75
MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena? Biomed Res Int (2016) 0.75
Circulating microRNAs as Potential Biomarkers of Infectious Disease. Front Immunol (2017) 0.75
Authors' reply. J Mol Diagn (2013) 0.75
Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreat Disord Ther (2015) 0.75
The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget (2017) 0.75
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 37.10
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 11.46
Quantification of mRNA using real-time RT-PCR. Nat Protoc (2006) 11.43
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods (2010) 6.25
Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech (2004) 5.97
Purification and characterization of PCR-inhibitory components in blood cells. J Clin Microbiol (2001) 5.78
Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res (2010) 5.29
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci (2010) 5.17
Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification. J Forensic Sci (1994) 4.02
miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ (2009) 3.94
Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem (2002) 3.72
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One (2010) 3.50
Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One (2010) 3.23
Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One (2010) 3.14
Identification and characterization of immunoglobulin G in blood as a major inhibitor of diagnostic PCR. J Clin Microbiol (2000) 3.02
Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer (2010) 2.95
Capacity of nine thermostable DNA polymerases To mediate DNA amplification in the presence of PCR-inhibiting samples. Appl Environ Microbiol (1998) 2.93
Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem (2010) 2.86
Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes (2009) 2.78
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene (1992) 2.63
Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev (2010) 2.51
Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol Biol (2007) 2.31
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol (2008) 2.30
A potent inhibitor of Taq polymerase copurifies with human genomic DNA. Nucleic Acids Res (1988) 2.26
Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc (2010) 1.89
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol (2010) 1.83
Mutants of Taq DNA polymerase resistant to PCR inhibitors allow DNA amplification from whole blood and crude soil samples. Nucleic Acids Res (2009) 1.72
MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res (2011) 1.66
Intracellular and extracellular microRNAs in breast cancer. Clin Chem (2010) 1.44
Improved microRNA quantification in total RNA from clinical samples. Methods (2010) 1.43
DNA endonucleases associated with the avian myeloblastosis virus DNA polymerase. Proc Natl Acad Sci U S A (1979) 1.40
Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiol (2011) 1.28
Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev (2007) 1.24
Differential expression of microRNAs with progression of gestation and inflammation in the human chorioamniotic membranes. Am J Obstet Gynecol (2007) 1.06
Endocannabinoid signalling: has it got rhythm? Br J Pharmacol (2010) 1.04
Glycolysis inhibitors negatively bias blood glucose measurements: potential impact on the reported prevalence of diabetes mellitus. J Clin Pathol (2007) 1.03
Detection of mouse mast cell-associated protease mRNA. Heparinase treatment greatly improves RT-PCR of tissues containing mast cell heparin. Am J Pathol (1995) 1.02
Detection of circulating fetal nucleic acids: a review of methods and applications. J Clin Pathol (2009) 1.01
Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques (2003) 0.98
Seasonal variation in haemodynamics and blood pressure-regulating hormones. J Hum Hypertens (2009) 0.95
Are changes in blood-ethanol concentration during storage analytically significant? Importance of method imprecision. Clin Chem Lab Med (2007) 0.92
Polymerase resistance to polymerase chain reaction inhibitors in bone*. J Forensic Sci (2009) 0.92
Chemistry behind Vegetarianism. J Agric Food Chem (2011) 0.88
A novel method to identify syncytiotrophoblast-derived RNA products representative of trisomy 21 placental RNA in maternal plasma. Methods Mol Biol (2008) 0.87
Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res (2003) 0.86
Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 0.85
Titration of heparinase for removal of the PCR-inhibitory effect of heparin in DNA samples. Mol Ecol (1997) 0.83
Can fluoride-oxalate and sodium citrate stabilise homocysteine levels after blood collection? Clin Chem Lab Med (2003) 0.82
Endogenous heparin--a protective marker in patients with myocardial infarction. Coron Artery Dis (2002) 0.82
Purification of RNA by SDS solubilization and phenol extraction. Cold Spring Harb Protoc (2010) 0.78
Altered degradation of circulating nucleic acids and oligonucleotides in diabetic patients. Diabetes Res Clin Pract (2007) 0.77
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA (2008) 5.68
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One (2010) 3.50
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Comprehensive splice-site analysis using comparative genomics. Nucleic Acids Res (2006) 3.30
Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One (2008) 3.19
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA (2002) 2.91
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS (2012) 2.63
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol (2007) 2.56
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood (2008) 2.30
Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet (2005) 2.29
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods (2003) 2.28
Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med (2013) 2.25
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr (2013) 2.15
Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS (2008) 2.12
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med (2007) 2.00
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med (2012) 1.88
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS (2002) 1.87
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood (2011) 1.85
Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One (2010) 1.83
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis (2005) 1.76
Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health (2010) 1.75
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS (2004) 1.75
Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2012) 1.69
Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS (2009) 1.67
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One (2011) 1.65
The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis (2005) 1.64
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis (2006) 1.62
Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis (2004) 1.58
Current trends of reproductive immunology practices in in vitro fertilization (IVF) - a first world survey using IVF-Worldwide.com. Am J Reprod Immunol (2012) 1.58
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57
HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS (2010) 1.57
The social context of food insecurity among persons living with HIV/AIDS in rural Uganda. Soc Sci Med (2011) 1.55
Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS (2013) 1.51
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr (2006) 1.49
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol (2010) 1.47
GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS (2013) 1.46
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol (2008) 1.45
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res (2012) 1.43
HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS (2009) 1.41
Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One (2012) 1.39
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res (2012) 1.37
Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS (2010) 1.36
Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One (2010) 1.35
CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology (2013) 1.30
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr (2012) 1.30
Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail (2009) 1.29
Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One (2013) 1.29
HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol (2010) 1.29
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell (2011) 1.28
Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF(65). PLoS One (2007) 1.28
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis (2006) 1.26
Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc (2012) 1.25
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.24
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol (2012) 1.24
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc (2011) 1.24
Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol (2006) 1.23
High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr (2013) 1.23